Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C

By Miller Michael   Dobs Adrian   Yuan Zhong   Battisti Wendy P.   Borisute Hannah   Palmisano Joanne  

Current Medical Research and Opinion, Vol. 20, Iss. 7, 2004-07 ,pp. : 1087-1094

Informa Healthcare

Access to resources Recommend Favorite

Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes*

By van Hoek M.   van Tol A.   van Vark-van der Zee L. C.   Jansen H.   Kastelein J. J. P.   Sijbrands E. J. G.   Dallinga-Thie G. M.  

Current Medical Research and Opinion, Vol. 25, Iss. 1, 2009-01 ,pp. : 93-101

Informa Healthcare

Access to resources Recommend Favorite

Metformin and β‐cell function in insulin‐treated patients with type 2 diabetes: A randomized placebo‐controlled 4.3‐year trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 730-733

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early glycaemic control among patients with type 2 diabetes and initial glucose‐lowering treatment: a 13‐year population‐based cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 771-780

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predictors of achieving HbA 1c <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study

By Valensi Paul  

Current Medical Research and Opinion, Vol. 29, Iss. 6, 2013-06 ,pp. : 601-609

Informa Healthcare

Access to resources Recommend Favorite